265 related articles for article (PubMed ID: 34103383)
21. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
Woodcock A; Vestbo J; Bakerly ND; New J; Gibson JM; McCorkindale S; Jones R; Collier S; Lay-Flurrie J; Frith L; Jacques L; Fletcher JL; Harvey C; Svedsater H; Leather D;
Lancet; 2017 Nov; 390(10109):2247-2255. PubMed ID: 28903864
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
24. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
[TBL] [Abstract][Full Text] [Related]
25. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
26. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.
Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P
Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
28. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
Donohue JF; Singh D; Munzu C; Kilbride S; Church A
Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
[TBL] [Abstract][Full Text] [Related]
29. Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Shukla S; Shah D; Martin A; Risebrough NA; Kendall R; Vogelmeier CF; Boucot I; Tombs L; Bjermer L; Jones PW; Kerwin E; Compton C; Maltais F; Lipson DA; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2021; 16():3105-3118. PubMed ID: 34916789
[TBL] [Abstract][Full Text] [Related]
30. Comparison table: Inhaled long-acting bronchodilators for treatment of COPD.
Med Lett Drugs Ther; 2020 Sep; 62(1606):e146-e147. PubMed ID: 32960874
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
32. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
Ramadan WH; Al Masri S; Rizk J
Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190
[TBL] [Abstract][Full Text] [Related]
33. Table: Correct Use of inhalers for COPD.
Med Lett Drugs Ther; 2020 Sep; 62(1606):e150-e154. PubMed ID: 32960876
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
35. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
36. Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
Bjermer L; Boucot IH; Maltais F; Kerwin EM; Naya IP; Tombs L; Jones PW; Compton C; Lipson DA; Vogelmeier CF
Int J Chron Obstruct Pulmon Dis; 2021; 16():1939-1956. PubMed ID: 34234425
[TBL] [Abstract][Full Text] [Related]
37. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
38. Healthcare professionals and pharmacovigilance of pediatric adverse drug reactions: a 5-year analysis of Adverse Events Reporting System Database of the Food and Drug Administration.
Bigi C; Tuccori M; Bocci G
Minerva Pediatr (Torino); 2022 Jun; 74(3):272-280. PubMed ID: 28211644
[TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]